Oncology

The American Cancer Society's National Consortium for Cancer Screening and Care outlined nine recommendations to bring screening rates back to pre-pandemic levels in a Feb. 16 report. 

Here are five moves reported by Becker's about the University of Texas MD Anderson Cancer Center since Jan. 10: 

AstraZeneca and Daiichi Sankyo's  Enhertu breast cancer drug significantly helped patients with HER2-low metastatic breast cancer in its phase 3 clinical trial, AstraZeneca said Feb. 21.

Yale Cancer Center invested $1.5 million to improve its hematology/oncology fellowship program, it said Feb. 18.

Rutgers Cancer Institute of New Jersey named Sanjay Goel, MD, director of its investigational therapeutics program, it said Feb. 16.

The University of Texas MD Anderson Cancer Center was awarded $31.7 million from the Cancer Prevention and Research Institute of Texas, the center said Feb. 16.

The University of Texas MD Anderson Cancer Center extended its partnership with Phoenix-based Banner Health for another 10 years, the cancer center said Feb. 15. 

Delayed screenings as a result of the COVID-19 pandemic have led to later-stage cancer diagnoses, a small study published Feb. 15 in JAMA Network Open suggests.

Yale Cancer Center recently made several leadership changes. 

The use of genomic sequencing to predict the likelihood that gastric cancer patients will  benefit from chemotherapy or from immunotherapy has been validated by findings in a study published Feb. 9 in Nature Communications.